The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Pharmaceutical (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly O. (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Zodiac Pharma (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Pharmaceutical (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly O.; MSD (Inst); Novartis (Inst); Pfizer; Roche/Genentech (Inst); Sanofi (Inst); Zodiac Pharma (Inst)
Research Funding - Amgen; AstraZeneca; AVEO; Bayer; BMS Brazil; Celgene; Daiichi Sankyo Pharmaceutical; Exelixis; Gilead Sciences; GlaxoSmithKline; Icon Cancer Care; IQVIA; Janssen; LabCorp; Lilly O.; Merck Serono; MSD; Nektar; Novartis; Novocure; Nuvisan; OBI Pharma; PAREXEL; Pfizer; PharmaMar; Polyphor; PPD; Psi Oragenics; Regeneron; Roche; Sanofi; Seagen; SERVIER; Syneos Health; Takeda; Trio Medicines; Worldwide Clinical Trials
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Daiichi Sankyo Pharmaceutical; Eisai; GlaxoSmithKline; Lilly O.; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort.
 
Soo-Chin Lee
Honoraria - ACT Genomics; AstraZeneca; Daiichi Sankyo Pharmaceutical; DKSH; Gilead Sciences; Lilly O.; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; MSD; Novartis; Pfizer; Roche
Research Funding - ACT Genomics; Eisai; Karyopharm Therapeutics; Pfizer; Taiho Oncology
Travel, Accommodations, Expenses - Amgen; Pfizer; Roche
 
Wei-Pang Chung
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Everest Medicine; Kyowa Kirin; Lilly O.; MSD; Pfizer; Roche; Viatris
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Everest Medicine; Gilead Sciences; Lilly O.; MSD; Pfizer
 
Roger Kai-Cheong Ngan
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly O.; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Zai Lab
Speakers' Bureau - AstraZeneca; Eisai; Lilly O.; MSD; Novartis; Pfizer; Sanofi; Zai Lab
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Janssen; Lilly; Merck; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); BMSi (Inst); Corvus Pharmaceuticals (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoSec (Inst); Roche (Inst); Seagen (Inst)
 
Carlos Barrios
No Relationships to Disclose
 
Teresa Tung
Employment - AstraZeneca
Stock and Other Ownership Interests - Abbvie; AstraZeneca